Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fc receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Fc receptor. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-001004-15 Sponsor Protocol Number: A1334-02 Start Date*: 2022-04-22
    Sponsor Name:ACCELERON PHARMA INC.
    Full Title: A Phase 1b/2 Open-Label, Multiple-Ascending Dose Study Followed by a Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Effica...
    Medical condition: Systemic sclerosis (SSc), a rare connective tissue disorder characterized by fibrosis, inflammation, and microvascular injury with heterogeneous presentations; Interstitial lung disease (ILD), a co...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037383 Pulmonary fibrosis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10042954 Systemic sclerosis pulmonary PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10025109 Lung involvement in systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000137-31 Sponsor Protocol Number: 2017-2019 Start Date*: 2017-12-19
    Sponsor Name:VU University Medical Center
    Full Title: Pulmonary Hypertension REversal in Clusters of Patients With Identical Pathobiological Substrates. 6-Mercaptopurine Proof-of-Concept Trial
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037454 Pulmonary vascular disorders HLGT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001067-36 Sponsor Protocol Number: 18588 Start Date*: 2016-11-21
    Sponsor Name:Bayer AG
    Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000984-30 Sponsor Protocol Number: 67896062PAH3001 Start Date*: 2024-01-03
    Sponsor Name:Janssen Pharmaceutical K.K.
    Full Title: A Multicenter, Open-label, Phase III Study to Assess the Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients (≥3 months to <15 years) with Pulmonary Arterial Hyperte...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-008200-40 Sponsor Protocol Number: VGFT-OD-0706 Start Date*: 2009-05-20
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)
    Medical condition: Diabetic Macular Edema (DME)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002345-64 Sponsor Protocol Number: 181501 Start Date*: 2015-11-12
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion with Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects with Immunoglobulin A Nephropathy (IgAN)
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000216-42 Sponsor Protocol Number: AC-065A404 Start Date*: 2017-07-11
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient’s self...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) DE (Completed) AT (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023396-25 Sponsor Protocol Number: SM101-201-sle-10 Start Date*: 2011-09-22
    Sponsor Name:SuppreMol GmbH
    Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003444-30 Sponsor Protocol Number: C0743T12 Start Date*: 2007-05-15
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005026-31 Sponsor Protocol Number: EFC6125 [AVE0005A/3001] Start Date*: 2006-04-24
    Sponsor Name:Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with ...
    Medical condition: pacientes con cáncer de ovario avanzado con ascitis maligna sintomática recurrente
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) HU (Completed) AT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003476-19 Sponsor Protocol Number: EFC10547 Start Date*: 2007-11-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.
    Medical condition: Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) BE (Completed) FR (Completed) ES (Completed) AT (Completed) PL (Completed) IT (Prematurely Ended) BG (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006657-63 Sponsor Protocol Number: 0881K1-4500-EU (B1801016) Start Date*: 2009-05-08
    Sponsor Name:Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
    Full Title: Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA).
    Medical condition: Rheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) state
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed) HU (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2007-000819-29 Sponsor Protocol Number: EFC10261 Start Date*: 2007-09-26
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced ...
    Medical condition: Patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) HU (Completed) IT (Completed) FR (Completed) AT (Prematurely Ended) EE (Completed) FI (Completed) SE (Completed) NL (Completed) BG (Completed) PT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002400-20 Sponsor Protocol Number: 81866 Start Date*: 2023-02-28
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Feasibility of empagliflozin as treatment for idiopathic pulmonary arterial hypertension
    Medical condition: Idiopathic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003778-27 Sponsor Protocol Number: 0881A8-205 Start Date*: 2005-03-30
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
    Full Title: A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent Asthma
    Medical condition: Moderate to severe asthmatics
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004756-20 Sponsor Protocol Number: EFC6546 Start Date*: 2007-09-19
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastat...
    Medical condition: Patients with metastatic androgen-independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) CZ (Completed) PT (Completed) ES (Completed) DK (Completed) HU (Completed) EE (Completed) BE (Completed) NL (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000820-42 Sponsor Protocol Number: EFC10262 Start Date*: 2008-06-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan...
    Medical condition: Patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin based regimen.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GR (Completed) NL (Completed) CZ (Completed) EE (Completed) ES (Completed) DK (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005724-17 Sponsor Protocol Number: AFLIBC06097 Start Date*: 2012-07-02
    Sponsor Name:Sanofi aventis Groupe
    Full Title: A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated...
    Medical condition: Colorectal Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DK (Completed) FI (Completed) DE (Completed) NL (Completed) IT (Completed) ES (Completed) IE (Completed) CZ (Completed) SI (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006562-42 Sponsor Protocol Number: RD-5103-007-06 Start Date*: 2008-02-21
    Sponsor Name:Derby Hospitals NHS Foundation Trust
    Full Title: An Observational and Exploratory Study to determine the effect of anti TNF Biologic Treatment in Rheumatoid Cachexia
    Medical condition: Cachexia in patients with Rheumatoid arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000048-89 Sponsor Protocol Number: AFLIBL06266 Start Date*: 2012-05-23
    Sponsor Name:sanofi-aventis France
    Full Title: A Multicenter, Single arm, Open Label Clinical Trial Evaluating Safety and Health-Related Quality of Life of Aflibercept in Combination with Irinotecan/5FU chemotherapy (FOLFIRI) in Patients with ...
    Medical condition: Colorectal Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 03:17:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA